---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-009852"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2024-02-01T23:59:59+00:00"
generated_at: "2026-06-06T12:28:37.198632+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# ARCA biopharma posts 2023 net loss of $5.3M ($0.37/share); cash $37.4M

## Summary
- Net loss improved to $5.3M from $9.9M in 2022; basic EPS loss $0.37 vs $0.69.
- Cash and equivalents $37.4M at Dec 31, 2023, down from $42.4M; runway through mid-2025.
- G&A expenses rose to $6.3M (2023) from $5.8M (2022) on higher professional and strategic review fees.
- R&D expenses fell to $1.0M from $4.7M due to lower clinical costs and headcount reduction.
- Strategic review ongoing with no defined timeline; potential merger, asset sale, or other alternatives.

## SEC filing metadata
- accession: 0000950170-24-009852
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2024-02-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000095017024009852/0000950170-24-009852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000095017024009852/abio-20240201.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-009852
- JSON: https://secwatch.observer/filing/0000950170-24-009852.json
- Plain text: https://secwatch.observer/filing/0000950170-24-009852.txt

## Key facts
- Earnings Releases
  Oruka Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023 was $5.3 million, or $0.37 per basic and diluted share, EPS $0.37 per basic and diluted share.
  - Period: the year ended December 31, 2023
  - Net income: Net loss for the year ended December 31, 2023 was $5.3 million, or $0.37 per basic and diluted share
  - EPS: $0.37 per basic and diluted share
  - Result: reported results
  source text: Net loss for the year ended December 31, 2023 was $5.3 million, or $0.37 per basic and diluted share, compared to $9.9 million, or $0.69 per basic and diluted share in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/907654/000095017024009852/0000950170-24-009852-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.